Lilly and J&J Face Off in Crohn’s Disease With Phase III Readouts at ACG 2024 (BioSpace)

At the American College of Gastroenterology Meeting, Eli Lilly and Johnson & Johnson presented Phase III results showing high remission rates for their Crohn’s disease drugs, Omvoh and Tremfya. J&J’s Tremfya achieved up to 66% remission at 48 weeks, offering options for subcutaneous and intravenous administration. Lilly’s Omvoh demonstrated a 96% response rate, with 87% of patients reaching remission, also showing efficacy in ulcerative colitis. Both companies are seeking approval for expanded use in Crohn’s, aiming to set new treatment standards.